Cancer News and Research

Latest Cancer News and Research

State roundup: Ohio and Washington prepare high risk pool plans; Calif. lawmakers consider 20 bills; Virginia wrestles with Medicaid issues

A popular piece of the health-care overhaul bans insurance companies from denying individual coverage or charging high premiums to people with pre-existing medical conditions. But for adults younger than age 65, that provision doesn't kick in until 2014. In the meantime, the federal government wants states to create temporary high-risk pools through which people with cancer, multiple sclerosis and diabetes who have been uninsured for at least six months can buy affordable coverage.

2 Jun 2010

Liver surgery improves survival in people with bowel cancer

Patients with bowel cancer that has spread to the liver and who are eligible for surgery, are around 40 per cent more likely to survive if they undergo an operation to remove the liver disease.

2 Jun 2010

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Roche, makers of ACCU-CHEK® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C. The "Chancellor's Award" recognizes and honors longstanding JDRF corporate partners.

From Roche Sequencing and Life Science 2 Jun 2010

Proton therapy offers life-changing benefits to children with cancer

The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

2 Jun 2010

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

The majority of Australians (58%) are worried about their brain health and the threat of age-related degenerative brain disease, according to a new survey. The national survey was commissioned by leading medical research institute Neuroscience Research Australia and polled 1000 Australians aged 18 to over 75.

2 Jun 2010

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

US Oncology, Inc., the nation's leading integrated oncology company, today announced its new iKnowMed™ Technology Platform to support community oncologists nationwide. This new platform enhances cancer care quality and practice efficiency through integrated, oncology-specific technologies that enable community oncologists to solve challenges in the areas of care delivery, drug management, and revenue cycle management.

2 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine technology

TapImmune Inc. announced that it has signed an exclusive Licensing Option agreement with Mayo Clinic, Rochester, MN, for clinical development of a breast cancer vaccine technology. The option to license this technology can be exercised after Phase I clinical trials under terms agreed between Mayo Clinic and TapImmune.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

New study provides further evidence of link between indoor tanning and melanoma

A new study has provided further evidence of a link between indoor tanning and melanoma, the deadliest form of skin cancer. Scientists at the University of Minnesota's School of Public Health and Masonic Cancer Centre claim that their study, which is published in the journal Cancer Epidemiology, Biomarkers and Prevention, "definitively links" the use of sunbeds to melanoma.

2 Jun 2010

Prototype breast cancer vaccine shows promising results in mice

US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Scientists discover key mechanism of cancer cells

Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Scientists have learned how a gene widely known for precisely positioning and sculpting various organs also controls the speed of cell division, a finding that could be useful for understanding the explosive growth of cancer cells or why increasing numbers of children are being born with genital and urinary tract malformations.

2 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

Cancer News and Research

Latest Cancer News and Research

State roundup: Ohio and Washington prepare high risk pool plans; Calif. lawmakers consider 20 bills; Virginia wrestles with Medicaid issues

Liver surgery improves survival in people with bowel cancer

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Proton therapy offers life-changing benefits to children with cancer

Survey: 58% of Australians worry about brain health, age-related degenerative brain disease

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

TapImmune signs Licensing Option agreement with Mayo Clinic for breast cancer vaccine technology

FDA grants priority review status to Eisai's eribulin NDA

New study provides further evidence of link between indoor tanning and melanoma

Prototype breast cancer vaccine shows promising results in mice

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Scientists discover key mechanism of cancer cells

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

New model reveals molecular basis of multiple hereditary exostoses

Cancer Research - Second Edition eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in